<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315093</url>
  </required_header>
  <id_info>
    <org_study_id>123456</org_study_id>
    <nct_id>NCT01315093</nct_id>
  </id_info>
  <brief_title>Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <brief_summary>
    <textblock>
      The addition of heparin increases pregnancy outcome parameters in poor responders undergoing
      In Vitro Fertilisation (IVF)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>no of oocytes retrieved</measure>
    <time_frame>egg recovery, 2 years</time_frame>
    <description>&gt;2 between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>2 years</time_frame>
    <description>Presence of fetal heart at transvaginal ultrasound at 6+2 gestational weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>live birth rate</measure>
    <time_frame>2 years</time_frame>
    <description>&gt;20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cancellation rate</measure>
    <time_frame>before ET, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage rate</measure>
    <time_frame>2 years</time_frame>
    <description>pregnancy loss &lt;20 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Heparin, Low-Molecular-Weight group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Heparin, Low-Molecular-Weight group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin, Low-Molecular-Weight</intervention_name>
    <description>Heparin from start till hcg test</description>
    <arm_group_label>Heparin, Low-Molecular-Weight group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>no heparin</intervention_name>
    <arm_group_label>Non Heparin, Low-Molecular-Weight group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  poor responders (age&gt;40, abnormal ovarian test, &lt;/=4 oocytes in previous cycle with
             conventional stimulation)

          -  infertility, indication for IVF

          -  no contraindications for heparin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>3rd Department of Obstetrics &amp; Gynecology</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Siristatidis Charalampos, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor, Director of the ARU</investigator_title>
  </responsible_party>
  <keyword>In Vitro Fertilisation</keyword>
  <keyword>poor responders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

